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Prostate radiotherapyBackground and purpose: For the first time, delivered dose to the rectum has been calculated and accumu-
lated throughout the course of prostate radiotherapy using megavoltage computed tomography (MVCT)
image guidance scans. Dosimetric parameters were linked with toxicity to test the hypothesis that deliv-
ered dose is a stronger predictor of toxicity than planned dose.
Material and methods: Dose–surface maps (DSMs) of the rectal wall were automatically generated from
daily MVCT scans for 109 patients within the VoxTox research programme. Accumulated-DSMs, repre-
senting total delivered dose, and planned-DSMs, from planning CT data, were parametrised using
Equivalent Uniform Dose (EUD) and ‘DSM dose-width’, the lateral dimension of an ellipse fitted to a dis-
crete isodose cluster. Associations with 6 toxicity endpoints were assessed using receiver operator char-
acteristic curve analysis.
Results: For rectal bleeding, the area under the curve (AUC) was greater for accumulated dose than
planned dose for DSM dose-widths up to 70 Gy. Accumulated 65 Gy DSM dose-width produced the stron-
gest spatial correlation (AUC 0.664), while accumulated EUD generated the largest AUC overall (0.682).
For proctitis, accumulated EUD was the only reportable predictor (AUC 0.673). Accumulated EUD was
systematically lower than planned EUD.
Conclusions: Dosimetric parameters extracted from accumulated DSMs have demonstrated stronger cor-
relations with rectal bleeding and proctitis, than planned DSMs.
 2017 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 123 (2017) 466–471
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).In prostate radiotherapy, the correlation between dose to rec-
tum and toxicity has been the focus of many research studies [1–
7]. The rectum is one of the dose-limiting organs when planning
intensity-modulated radiotherapy (IMRT) to the prostate due to
the risk of radiation-induced adverse effects. Modern systems for
inverse IMRT treatment planning iteratively seek to achieve an
optimal plan, delivering maximal dose to the tumour volume and
minimal dose to healthy organs. Current normal tissue complica-
tion probability (NTCP) models and conventional treatment plan-
ning constraints are based upon dose–volume histogram (DVH)
data to minimise the risk of toxicity. With ever improving disease
control [8,9] and survival rates [10], post-treatment quality of life
becomes an increasingly significant consideration during treat-
ment planning, alongside target coverage.The DVH-based approach to radiotherapy treatment planning
has been criticised for lacking in spatial dose consideration [2]. Con-
sequently, accumulation of DVHs is not dosimetrically representa-
tive and results in false overestimations of dose. A review by
Landoni et al. [11] emphasises the need to assess associations
between spatial dose patterns and late toxicity [12], particularly
as resultsmay reveal inhomogeneous intra-organ radiosensitivities.
Several groups have explored alternative approaches for
parametrisation of dose distributions in order to establish links
with toxicity. Methods have included dose–surface histograms
[1,5,13,14], dose–surface maps [1,5,15], dose–line histograms
[14], principal component-based pattern analysis [16], and voxel-
based approaches for identifying rectal subregions [2,6,7]. These
studies have been limited in their analysis by the availability of
planned dose data only, based on a single anatomical snapshot in
time.
A common recommendation in the literature has been the need
to establish dose-toxicity models based on delivered dose [17].
However, this has proven technically challenging to date due to
Table 1
Baseline characteristics for the 109 VoxTox participants. Prescribed dose to the
prostate was 74 Gy in 37 fractions over 7.5 weeks. All patients were treated with
androgen deprivation therapy. IBD = inflammatory bowel disease, IQR = interquartile
range, PSA = prostate-specific antigen, SD = standard deviation.
Clinical data for VoxTox patients (n = 109)
Age, years
Median (IQR) 68 (64–71)
Range 51–80
T stage, n (%)
T1A/T1B/T1C/T1X 24 (22%)
T2A/T2B/T2C/T2X 34 (31%)
T3A/T3B/T3X 45 (41%)
T4 0
Not known 6 (6%)
Gleason score, n (%)
66 23 (21%)
7 44 (40%)
P8 39 (36%)
Not known 3 (3%)
PSA (ng/ml)
Median (IQR) 11 (7–20)
Mean (SD) 20 (30)
Not known 3 (3%)
Clinical history
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addressed within the VoxTox Research Programme [18] where
contours generated from on-treatment megavoltage computed
tomography (MVCT) image guidance scans are used to calculate
daily delivered dose. This approach has made it possible to account
for the effect of interfractional anatomical variation. Total deliv-
ered dose can be estimated by accumulating daily delivered dose
throughout the course of radiotherapy. Studies by the VoxTox
group have demonstrated that the rectum moves more than previ-
ously predicted based on estimates from prostate motion [19], and
that planned dose is not equal to delivered dose [20].
The dose–surface map (DSM) approach has been implemented
within this study as a solution enabling meaningful accumulation
and conservation of geometric information, an advantage over
the DVH methodology. The concept of accumulating DSMs to esti-
mate total delivered dose has been applied previously for the blad-
der [13]. By extracting spatial parameters from DSMs of delivered
dose, and linking with the archive of patient follow-up data avail-
able within VoxTox, it was hypothesised that stronger correlations
could be established with late toxicity than previously achievable
using planned dose alone. Ultimately, improved dose-toxicity
modelling based on delivered dose could facilitate real-time in sil-
ico prediction of NTCP within the clinical pathway.Diabetes 10 (9%)
Hypertension 35 (32%)
IBD or diverticular disease 7 (6%)
Previous pelvic surgery 7 (6%)
Haemorrhoids past 12 months 3 (3%)
Any previous TURP 9 (8%)
Not known 9 (8%)Material and methods
VoxTox study design & patient information
The VoxTox research programme is an observational study link-
ing radiation dose to toxicity outcomes [18,20]. It received
approval from the National Research Ethics Service (NRES) Com-
mittee East of England (13/EE/0008) in February 2013 and is part
of the UK Clinical Research Network Study Portfolio (UK CRN ID
13716).
One hundred and nine prostate cancer patients were selected
from the discovery cohort of the VoxTox research programme
[18]. This cohort (Table 1) comprised patients treated prior to the
formal collection of baseline data, but for whom prospective
follow-up data of at least 2 years were available (median 4 years).
Early VoxTox patients were selected based on expected benefit
from IMRT rather than conventional 3D conformal radiotherapy.
Patients in this study were included on the basis of availability of
pre-existing toxicity status from clinical notes, or no reported tox-
icity, and was limited to those prescribed IMRT to a dose of 74 Gy
in 37 fractions, the standard of care in the UK at the time [21]. Vox-
Tox patients are treated with TomoTherapy (Accuray, Sunnyvale,
CA). Manual contouring of the anatomy on the kilovoltage com-
puted tomography (kVCT) planning scan was performed according
to local procedures [19], adapted from clinical trials. Daily MVCT
image guidance scans were acquired immediately prior to treat-
ment delivery for the purposes of online target localisation [22].
Following our department protocol, scans were inspected for rectal
dilation and if deemed excessive, remedial action was taken prior
to delivery of radiation therapy [23].Dose–surface map construction & dose accumulation
Within the VoxTox research programme, MVCT scans are mul-
tifunctional; primarily for the purpose of routine image guidance,
they also provide a platform for calculation of delivered dose.
The rectum was identified on each MVCT image series using an
in-house autocontouring system based on a customised Chan-
Vese segmentation algorithm [24]. Delivered dose was indepen-
dently calculated using a locally implemented ray-tracing algo-
rithm [25,26] and the rectal contour-of-the-day, accounting for
inter-fraction motion. Automation and integration of dose calcula-tion and contouring systems were essential for large-scale process-
ing of the 4142 scans in this study.
Planned and daily DSMs were generated based on algorithms
described by Buettner et al. [1] and Murray et al. [15]. The rectal
wall was considered the structure of interest, and was treated as
a tubular surface rather than a volume. Contours were virtually
‘cut’ along the superior–inferior axis and ‘unfolded’ to a two-
dimensional plane. The ‘cutting point’ was identified as the point
on the contour surface directly posterior to the centre of mass of
the rectal outline, on each CT slice [20].
The height of the planned-DSM was defined by the number of
slices of the manually contoured rectum on the kV planning scan
(slice thickness 3 mm). The circumference of the rectal contour
on each slice was normalised such that the unfolded width of the
planned-DSM was equal to the height. Daily delivered DSMs calcu-
lated from the image-guidance MVCT scans (slice thickness 6 mm)
were normalised to the same width as the planned-DSM but were
restricted in height by the field of view (FOV), resulting in a shorter
DSM, as shown in Fig. 1.
Rectal DSMs were calculated for each treatment fraction, and
corrected for daily couch shifts. For the purposes of dose accumu-
lation, any ‘missing’ dose data cropped by the restricted FOV supe-
riorly or inferiorly were substituted from the planned-DSM [20] in
order to maintain common dimensions between final
accumulated-DSM and planned-DSM. The final accumulated-DSM
was resampled to match the 3 mm resolution of the planned-
DSM, producing an easily comparable and interpretable spatial
representation of total delivered dose to the rectal wall throughout
the course of prostate radiotherapy [25] (illustrated in Fig. 1).
The use of planned-DSM data as a surrogate beyond the bound-
aries of the MVCT FOV was considered an acceptable estimate
under the assumption that the relative anatomical motion of the
rectum becomes more confined by surrounding musculature as
the distance from the prostate increases [20]. However, this could
have reduced potential differences between planned and accumu-
lated dose, and was a limitation of the analysis.
Fig. 1. Generation of planned, daily and accumulated dose surface maps.
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Dose was parametrised from DSMs using two methods imple-
mented in MATLAB (MathWorks, Natick, MA):
1. Calculation of Equivalent Uniform Dose (EUD)
2. Fitting of DSM ‘dose-widths’ to discrete isodose clusters
EUD reduces the dose information extracted from the DSMs to a
single generalised value which allows comparison between inho-
mogeneous dose distributions [27]. An ‘a’ value of 11.11 was used
in the EUD calculation [28]. Spatial dose information was gener-
ated by reproducing Buettner’s ellipse-fitting method [1], reporting
the most significant dose quantifier, the lateral extent, termed here
the ‘DSM dose-width’.
For a given isodose level, a binary image was created from the
DSM by assigning a pixel value of 1 to doses greater than or equal
to the nominated isodose, with lower doses assigned a value of 0.
An ellipse was then fitted to the largest central cluster. The maxi-
mum lateral extent of the ellipse was projected onto the DSM axis,
accounting for any rotation with respect to the DSM coordinate
system. The resulting DSM dose-width, expressed as a the percent-
age of total normalised DSM width, allowed parametrisation of the
geometrical dose distribution which would have been masked
using a DVH approach.
For each patient, EUD and DSM dose-widths for isodose levels of
30, 40, 50, 60, 65, and 70 Gywere calculated from planned-DSM and
accumulated-DSM. Doses less than 30 Gywere not included as DSM
dose-width results became dominated by extrapolated values
greater than 100%, indicating that the entire rectal circumference
was receiving less than or equal to the selected isodose level. This
was identified as a limitation of the ellipse fitting method when
seeking to analyse low dose toxicity correlations. Doses greater
than 70 Gy were also excluded from toxicity analyses due to the
increasing frequency of 0% DSM dose-widths, indicating that doses
greater than or equal to the selected isodose level were not received
by the rectal wall. Only 49/109 patients recorded a non-zero result
from accumulated DSM at 74 Gy, reducing to 10/109 at 75 Gy, com-
pared with 106/109 and 64/109 respectively from planned-DSM. It
was identified that a 0% DSM result could conceal information lead-
ing to misinterpretation of data when performing AUC calculations
so results at these isodose levels were not reported. Despite these
restriction, the dose levels included within this study incorporate
the 39–61 Gy range at which Buettner [1] determined significant
correlations between lateral extent and toxicity.Study specific clinical reporting forms were developed for
robust collection of toxicity data, and raw data were used to pop-
ulate recognised systems, including: Common Terminology Crite-
ria for Adverse Events (CTCAE) v4.03 [29], Late Effects of Normal
Tissues/Subjective, Objective, Management, Analytic (LENT SOMA)
scores [30]; Radiation Therapy Oncology Group (RTOG) grading
system [31]; University of California, Los Angeles, Prostate Cancer
Index (UCLA-PCI) questionnaire [32]. Receiver Operator Character-
istic (ROC) curves (Fig. 2) were generated using SPSS (IBM
23.0.0.2) to evaluate the link between dosimetric parameters
extracted from planned and accumulated DSMs, and the six most
prevalent clinical endpoints, listed in Table 2.
The mean area under the curve (AUC), with associated upper
and lower 95% confidence intervals (CIs), was calculated for each
ROC curve as a measure of the level of association between dosi-
metric parameter and toxicity. An ideal correlation would have
an AUC of 1. Results were reported for dosimetric parameters with
AUCP 0.6 and lower 95% CIP 0.5, considered statistically signifi-
cant by Gulliford et al. [33].
Results
Rectal bleeding
Twenty-eight patients reported rectal bleeding CTCAE PGrade
1, which was equivalent to PGrade 2 (LENT SOMA). The AUC
was greater for all accumulated DSM dose-widths than planned
DSM dose-widths up to 70 Gy (Table 3). At 30, 40 and 60 Gy, the
lower 95% CI boundaries for the planned DSM dose-widths
extended below 0.5, but remained above this threshold for the cor-
responding accumulated DSM dose-widths (Fig. 3a). The strongest
spatial predictor of rectal bleeding was accumulated 65 Gy DSM
dose-width (AUC 0.664), and the largest difference between
planned and accumulated DSM dose widths was at 60 Gy (AUC dif-
ference 0.035).
Overall, for both planned and accumulated DSMs, the AUC was
greater for EUD than from respective DSM dose-widths, with the
strongest predictor of rectal bleeding being accumulated-EUD
(AUC 0.682).Proctitis
The RTOG definition of proctitis considers urgency and fre-
quency of bowel movements, as well as the presence of rectal
mucous/blood. Eighteen patients reported RTOG proctitis PGrade
Fig. 2. Receiver operator characteristic curves for (a) rectal bleeding with 65 Gy
DSM dose-widths, (b) rectal bleeding with EUD, and (c) proctitis with EUD.
Table 2
Clinical endpoints, scoring systems and incidence rates of the 6 most frequently
reported toxicities within the patient sample (*Data were missing for 4 patients so
sample size was reduced accordingly).
Clinical Endpoint Scoring System Incidence % (n)
Rectal Bleeding PGrade 1
(Rectal Bleeding PGrade 2)
CTCAE [29]
(LENT SOMA [30])
25.7 (28/109)
Proctitis PGrade 2 RTOG [31]/
Gulliford [35]
16.5 (18/109)
Sphincter Control PGrade 1 LENT SOMA [30] 10.1 (11/109)
Rectal Pain PGrade 1 CTCAE [29]/
LENT SOMA [30]
15.6 (17/109)
Bowel bother PGrade 1 UCLA-PCI [32] 30.7 (32/105*)
Bowel bother PGrade 2 UCLA-PCI [32] 11.5 (12/105*)
Table 3
Mean Area Under the Curve (AUC) for planned and accumulated DSM dose-widths
and EUD corresponding to rectal bleeding PGrade 2 (LENT SOMA) and PGrade 1
(CTCAE), n = 28/109. The greater AUC of each parameter has been presented in bold.
Dose Level (Gy) Mean AUC (Planned) Mean AUC (Accumulated)
30 0.606 0.629
40 0.603 0.621
50 0.627 0.635
60 0.608 0.643
65 0.635 0.664
70 0.659 0.642
EUD 0.673 0.682
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eter with AUCP 0.6 and lower 95% CIP 0.5 (Fig. 3b). Accumulated
DSM dose-widths had greater AUC than planned DSM dose-widthsat 50, 60, 65 and 70 Gy, and were equivalent at 40 Gy. At 30 Gy, the
AUC of planned DSM dose-width was slightly higher than the accu-
mulated AUC (0.004 difference).Remaining clinical endpoints
For the remaining clinical endpoints (LENT SOMA sphincter
control PGrade 1; CTCAE/LENT SOMA subjective rectal pain
PGrade 1; UCLA-PCI ‘‘Overall, how big a problem have your bowel
habits been for you during the last 4 weeks?”, bowel bother
PGrade 1 andPGrade 2), EUD and DSM dose-widths had little dis-
criminatory power from planned-DSM or accumulated-DSM. No
dosimetric parameter was found to have AUCP 0.6 and lower
95% CIP 0.5. Results have been included as supplementary data.Equivalent uniform dose
EUD produced the greatest AUCs for rectal bleeding and procti-
tis, indicating a stronger association than the spatial parameters
investigated. In both cases, accumulated-EUD generated a higher
AUC than planned-EUD. For all patients, EUD of accumulated-
DSM was lower than that of planned-DSM (mean difference
2.2 Gy, standard error 0.3 Gy, range [0.3, 7.1] Gy).Discussion
Radiation dose received by the rectal wall during prostate
radiotherapy was calculated and accumulated using DSMs. Geo-
metric aspects of dose distribution - information not distinguish-
able from DVHs – were parametrised using DSM dose-widths.
EUD was calculated to compare planned and accumulated DSMs
using a single metric. Extracted dosimetric parameters were eval-
uated against six clinical endpoints reported by patients within
the VoxTox research programme. Previous dose-toxicity investiga-
tions in the literature have been limited to planned dose only. This
study has demonstrated, for the first time, that delivered dose can
Fig. 3. High-low plots of mean AUC and 95% confidence intervals for (a) Rectal
Bleeding and (b) Proctitis, where results were considered significant if mean AUC
P0.6 and lower 95% CI P0.5.
470 Correlating delivered dose with toxicitybe a stronger predictor of toxicity in the case of rectal bleeding and
proctitis in prostate radiotherapy.
Toxicity rates reported in the literature have been variable. The
rate of bowel toxicity PGrade 2 (CTCAE), 5 year cumulative inci-
dence, amongst VoxTox prostate patients was 17%. This falls within
the bowel toxicityPGrade 2 (RTOG) range of 13.7–24.9% for IMRT
over the same timeframe, reported by Dearnaley et al. [9] and
Wortel et al. [34], respectively. The rates of incidence indicate that
toxicity remains an important clinical issue.Many associations were found between DSM dose-widths with
rectal bleeding. Accumulated DSMs generated greater AUCs than
planned DSMs for 5 DSM dose-width levels up to 70 Gy. The stron-
gest correlation between rectal bleeding and any spatial parameter
was the 65 Gy DSM dose-width from accumulated dose (AUC
0.664). At 30, 40 and 60 Gy, accumulated DSM dose-widths pro-
duced AUCP 0.6 and lower 95% CIP 0.5, where corresponding
planned DSM dose-widths did not. These thresholds were consid-
ered indicative of significance following the methods of Gulliford
et al. [33]. The greatest difference between planned and accumu-
lated AUCs was observed at the 60 Gy DSM dose-width. Overall,
the results compared well with the findings of Buettner et al. [1]
who reported the most significant correlation with rectal bleeding
to be the 61 Gy lateral extent (AUC 0.66), derived from planned
dose data.
Accumulated EUD was found to have the strongest correlation
overall with rectal bleeding (AUC 0.682), and was the only predic-
tor of proctitis (AUC 0.673).
For all patients, accumulated-EUDwas systematically lower than
planned-EUD. A contributory factor was possibly the inherent blur-
ring of high dose regions during accumulation. Upon visual inspec-
tion of daily DSMs, the differences in size, shape and position of
the high dose region due to anatomical variation was clearly visible
(for example, shown indeep red in Fig. 1). During accumulation, high
doses were superimposed in overlap regions, but reduced where
isodose edges differed, due to averaging over the full course of radio-
therapy. This affected the maximum dose of the accumulated-DSM,
on which EUD calculation was heavily weighted.
The dose-blurring effect could also have been responsible for
the increased frequency of 0% DSM dose-width results at high
dose levels from accumulated-DSMs with respect to planned-
DSMs. At 70 Gy, 4/109 patients recorded a 0% accumulated DSM
dose-width (including 1 patient experiencing toxicity), whereas
all corresponding planned DSM dose-widths had non-zero
results. Furthermore, dose levels could not be considered indepen-
dent variables, as a low 70 Gy DSM dose-width was likely to be
associated with a low 65 Gy DSM dose-width, and a cooler plan
overall. These issues were not accounted for within the scope of
this study.
The generally lower reported values for EUD and DSM dose-
widths from accumulated dose compared with planned dose
should not be interpreted as delivered treatment erring on the ’safe
side’ in terms of dose to rectum. Where current NTCP models are
based on planned dose, the presented results suggest that the same
magnitude of risk would be associated with a systematically lower
delivered dose.
The findings show that the difference in dose between patients
with and without rectal toxicity is greater from delivered dose than
planned dose. This indicates that dosimetric parameters from
accumulated-DSMs could provide new information to improve
understanding of the relationship between dose and toxicity. The
single parameter EUD was a superior predictor of rectal bleeding
and proctitis than spatial dose quantifiers. However, DSM-dose
widths produced several strong correlations with rectal bleeding,
and for 5/6 dose levels, accumulated dose generated AUC values
greater than planned dose.
The ability to preserve and accumulate spatial dose information
throughout treatment is a novel process requiring careful consider-
ation of data interpretation and parametrisation. Future work may
involve exploring alternative methods for geometrical quantifica-
tion of spatial dose distributions in order to determine stronger
correlations with toxicity. Analysis of delivered dose to the rectal
wall could facilitate the identification of inhomogeneous intra-
organ radiosensitivities, allowing shape-based dose constraints to
be derived. Spatial considerations could complement current
DVH-based approaches to treatment planning.
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limitations of the static planned DVH, the aim is to determine
those parameters strongly associated with rectal toxicity which
could be incorporated into multivariate NTCP models. Emerging
dose quantifiers could be integrated into planning constraints, as
well as being prospectively monitored throughout treatment.
Delivered dose can be accumulated in ’real-time’ and analysed
with each fraction, allowing on-treatment toxicity risk assessment.
Towards the end of the course of treatment, if toxicity prediction
was found to be lower than planned, the decision could be made
to increase the total delivered dose to the target. The potential
scope for further individualisation and adaptation of treatment
could ultimately reduce rates of toxicity incidence and improve
clinical outcomes.Conclusion
Parametrisation of delivered dose to the rectal wall during
prostate radiotherapy has revealed stronger correlations with
rectal bleeding and proctitis than achievable from planned dose.
New information from accumulated delivered dose could lead to
improved dose-toxicity modelling in the future, with the aim of
reducing post-treatment toxicity.Conflict of interest
The authors declare no conflicts of interest.
Acknowledgements
The authors would like to thank the patients who participated
in the study, the referring physicians, and VoxTox Research
Facilitator, Michael Simmons. LEAS is supported by the University
of Cambridge W D Armstrong Trust Fund; AMB, MRR and KH are
supported by the VoxTox Programme Grant, which is funded by
Cancer Research UK (CRUK); JES was supported by a CRUK Clinical
Research Fellowship; DJN is supported by a CRUK Clinical Research
Fellowship; NGB is Principle Investigator of the CRUK VoxTox
Programme and is supported by the NIHR Cambridge Biomedical
Research Centre.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.radonc.2017.04.
008.
References
[1] Buettner F, Gulliford SL, Webb S, Sydes MR, Dearnaley DP, Partridge M.
Assessing correlations between the spatial distribution of the dose to the rectal
wall and late rectal toxicity after prostate radiotherapy: an analysis of data
from the MRC RT01 trial (ISRCTN 47772397). Phys Med Biol 2009;54:6535–48.
[2] Acosta O, Dréan G, Ospina JD, et al. Voxel-based population analysis for
correlating local dose and rectal toxicity in prostate cancer radiotherapy. Phys
Med Biol 2013;58:2581–95.
[3] Wortel RC, Witte MG, van der Heide UA, et al. Dose–surface maps identifying
local dose-effects for acute gastrointestinal toxicity after radiotherapy for
prostate cancer. Radiother Oncol 2015;117:515–20.
[4] Coloigner J, Fargeas A, Kachenoura A, et al. A novel classification method for
prediction of rectal bleeding in prostate cancer radiotherapy based on a semi-
nonnegative ICA of 3D planned dose distributions. IEEE J Biomed Health
Informat 2015;19:1168–77.
[5] Buettner F, Gulliford SL, Webb S, Partridge M. Modeling late rectal toxicities
based on a parameterized representation of the 3D dose distribution. Phys Med
Biol 2011;56:2103–18.
[6] Dréan G, Acosta O, Ospina JD, et al. Identification of a rectal subregion highly
predictive of rectal bleeding in prostate cancer IMRT. Radiother Oncol
2016;119:388–97.[7] Gael Dréan G, Acosta O, Lafond C, Simon A, de Crevoisier R, Haigron P.
Interindividual registration and dose mapping for voxelwise population
analysis of rectal toxicity in prostate cancer radiotherapy. Med Phys
2016;43:2721–30.
[8] Dearnaley DP, Jovic G, Syndikus I, et al. Escalated-dose versus control-dose
conformal radiotherapy for prostate cancer: long-term results from the MRC
RT01 randomised controlled trial. Lancet Oncol 2014;15:464–73.
[9] Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus
hypofractionated high-dose intensity-modulated radiotherapy for prostate
cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP
trial. Lancet Oncol 2016;17:1047–60.
[10] Cancer Research UK. Prostate cancer survival statistics. http://
www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-
by-cancer-type/prostate-cancer/survival#ref-2. Accessed: November 2016
[11] Landoni V, Fiorino C, Cozzarini C, Sanguineti G, Valdagni R, Rancati T. Predicting
toxicity in radiotherapy for prostate cancer. Phys Med 2016;32:521–32.
[12] Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology
Group (RTOG) and the European organization for research and treatment of
cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341–6.
[13] Palorini F, Botti A, Carillo V, et al. Bladder dose–surface maps and urinary
toxicity: Robustness with respect to motion in assessing local dose effects.
Physica Med. 2016;32:506–11.
[14] Hamlett LJ, McPartlin AJ, Maile EJ, et al. Parametrized rectal dose and
associations with late toxicity in prostate cancer radiotherapy. Br J Radiol
2015;88:20150110.
[15] Murray J, McQuaid D, Dunlop A, et al. Su-e-j-14: a novel approach to evaluate
the dosimetric effect of rectal variation during image guided prostate
radiotherapy. Med Phys 2014;41:157.
[16] Söhn M, Alber M, Yan D. Principal component analysis-based pattern analysis
of dose–volume histograms and influence on rectal toxicity. Int J Radiat Oncol
Biol Phys 2007;69:230–9.
[17] Jaffray DA, Lindsay PE, Brock KK, Deasy JO, Tomé W. Accurate accumulation of
dose for improved understanding of radiation effects in normal tissue. Int J
Radiat Oncol Biol Phys 2010;76:S135–9.
[18] CompRT VoxTox. Linking radiation dose at the voxel level with toxicity. http://
www.comprt.org/research/voxtox. Accessed: August 2016
[19] Scaife JE, Harrison K, Romanchikova M, et al. Random variation in rectal
position during radiotherapy for prostate cancer is two to three times greater
than that predicted from prostate motion. Br J Radiol 2014;87:20140343.
[20] Scaife JE, Thomas SJ, Harrison K, et al. Accumulated dose to the rectum,
measured using dose-volume histograms and dose-surface maps, is different
from planned dose in all patients treated with radiotherapy for prostate
cancer. Br J Radiol 2015;88:20150243.
[21] National Institute for Health and Care Excellence (NICE). Prostate cancer:
diagnosis and treatment (CG175). http://www.nice.org.uk/guidance/cg175.
Accessed: November 2016 (2014)
[22] Burnet NG, Adams EJ, Fairfoul J, et al. Practical aspects of implementation of
helical tomotherapy for intensity-modulated and image-guided radiotherapy.
Clin Oncol 2010;22:294–312.
[23] Thomas SJ, Ashburner M, Tudor GSJ, et al. Intra-fraction motion of the prostate
during treatment with helical tomotherapy. Radiother Oncol 2013;109:482–6.
[24] Sutcliffe MP, Harrison K, Scaife JE, Parker MA, Romanchikova M. Auto-
contouring of the rectum on megavoltage computed tomography images.
Cambridge University Engineering Department Technical Report 2015;CUED/
C-MICROMECH/TR. 100.
[25] Thomas SJ, Romanchikova M, Harrison K, et al. Recalculation of dose for each
fraction of treatment on TomoTherapy. Br J Radiol 2016;89:20150770.
[26] Thomas SJ, Eyre KR, Tudor GSJ, Fairfoul J. Dose calculation software for helical
tomotherapy, utilizing patient ct data to calculate an independent three-
dimensional dose cube. Med Phys 2012;39:160–7.
[27] Niemierko A. Reporting and analyzing dose distributions: a concept of
equivalent uniform dose. Med Phys 1997;24:103–10.
[28] Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO. Radiation dose-volume
effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys
2010;76:123–9.
[29] U.S. department of health and human services NIoH. National Cancer Institute.
Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 2010.
Accessed: July 2016. URL: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE4.032010-
06-14QuickReference5x7.pdf.
[30] LENT SOMA tables table of contents. Radiother Oncol 1995;35:17–60.
[31] Pilepich M, Asbell S, Krall J, et al. Correlation of radiotherapeutic parameters
and treatment related morbidity—analysis of RTOG study 77–06. Int J Radiat
Oncol Biol Phys 1987;13:1007–12.
[32] Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA prostate
cancer index: development, reliability, and validity of a health-related quality
of life measure. Med Care 1998;36:1002–12.
[33] Gulliford SL, Partridge M, Sydes MR, Andreyev J, Dearnaley DP. A comparison
of dose–volume constraints derived using peak and longitudinal definitions of
late rectal toxicity. Radiother Oncol 2010;94:241–7.
[34] Wortel RC, Incrocci L, Pos FJ, et al. Late side effects after image guided intensity
modulated radiation therapy compared to 3D-conformal radiation therapy for
prostate cancer: results from 2 prospective cohorts. Int J Radiat Oncol Biol Phys
2016;95:680–9.
[35] Gulliford SL, Foo K, Morgan RC, et al. Dose–volume constraints to reduce rectal
side effects from prostate radiotherapy: Evidence from MRC RT01 trial ISRCTN
47772397. Int J Radiat Oncol Biol Phys 2010;76:747–54.
